This is an AMP page which is for mobile devices.

View Non AMP page

Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SLNO - Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps

SLNO - Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps

September, 24 2025 08:05 AM Soleno Therapeutics Inc.

2025-09-24 08:05:58 ET

More on Acadia Pharma, Soleno Therapeutics

Soleno Therapeutics: Patient Death Unrelated To Vykat, But Safety Concerns May Undermine Launch
ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Soleno drops on death of patient treated with Vykat XR
Acadia raises 2025 NUPLAZID guidance to $665M–$690M as DAYBUE accelerates community uptake

For further details see:

Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps

Stock Information

Company Name:	Soleno Therapeutics Inc.
Stock Symbol:	SLNO
Market:	NASDAQ
Website:	soleno.life

SLNO SLNO Quote SLNO Short SLNO News SLNO Articles SLNO Message Board

Get SLNO Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.